TCG NEWS
Dr. Hui Tian joins The Column Group as Venture Partner
The Column Group announces the hiring of Dr. Hui Tian. Previously, Dr. Tian was a founding member of NGM Biopharmaceuticals and most recently served as
Dr. Sarah Hymowitz Promoted from Venture Partner to Partner
The Column Group announces the promotion of Dr. Sarah Hymowitz from Venture Partner to Partner. Dr. Hymowitz has been with TCG since 2021.
Dr. Millie Ray Promoted from Principal to Partner
The Column Group announces the promotion of Dr. Millie Ray from Principal to Partner. Dr. Ray has been with TCG since 2017.
Mr. Jeff Goater joins The Column Group as Venture Partner
The Column Group announces the hiring of Mr. Jeff Goater. Previously, Mr. Goater served as Chief Executive Officer of Surface Oncology. Prior to Surface, he
Dr. Sarah Gillmor Hymowitz joins The Column Group as Venture Partner
The Column Group announces the hiring of Dr. Sarah Gillmor Hymowitz. Previously, Dr. Hymowitz spent 22 years at Genentech rising to Vice President of Protein
TCG Launches the Swanson Fellowship Program and Dr. Tobias Schmid joins as first Fellow
Widely considered to be the father of the biotechnology industry, Robert Swanson changed the world when he founded Genentech with Herbert Boyer in 1976. TCG’s
TCG Announces the Addition of TCG iPartners
TCG’s iPartners represents a new ideation advisory group comprised of leading academic investigators and biotech entrepreneurs. Working closely with TCG’s Swanson Fellows and our core
Dr. Eric Olson joins The Column Group as Science Partner
The Column Group announced the recruitment of Dr. Eric Olson to the firm’s renowned group of Science Partners. Dr. Olson is the founding Chair of
Dr. John Josey joins The Column Group as Venture Partner
The Column Group announces the hiring of Dr. John Josey. Previously, Dr. Josey served as the President, Chief Executive Officer and a member of the
The Column Group Raises a $725 Million Fourth Fund
The Column Group (TCG), a biotech venture capital firm focused on building innovative drug discovery companies, announced the closing of The Column Group IV (TCG
